Antiretroviral Therapy for HIV-2 Infection in Senegal

塞内加尔针对 HIV-2 感染的抗逆转录病毒治疗

基本信息

  • 批准号:
    7367162
  • 负责人:
  • 金额:
    $ 62.92万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2005
  • 资助国家:
    美国
  • 起止时间:
    2005-06-07 至 2010-02-28
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): The overarching goals of this proposal are to further our understanding of the effect of potent antiretroviral therapy (ART) on Human Immunodeficiency Virus Type 2 (HIV-2) infection. HIV-2 is generally less pathogenic than HIV-1. Compared to HIV-1, HIV-2 infection is characterized by a much longer asymptomatic stage, lower plasma viral loads, slower decline in CD4+ T cell count, decreased mortality rate due to AIDS, lower rates of mother to child transmission, and lower rates of sexual transmission. Nonetheless, a significant proportion of HIV-2 infected individuals eventually progress to AIDS. Antiretrov'iral therapy is becoming increasingly available in resource-limited settings. In Senegal where both HIV-1 and HIV-2 are found, a national program of providing antiretroviral treatment (ART) for those with AIDS, CD4+ T cell counts less than 200/mm3, or CD4+ T cell counts less than 350/mm3 and clinical symptoms has been established. However, the effects of ART on outcome, immunologic response, viral load, dynamics and evolution, HIV-2 drug resistance and fitness in HIV-2 infected individuals are largely unknown. Our longstanding longitudinal cohort of HIV-2 infected subjects from Dakar, Senegal provides a unique opportunity to study the role ART plays in suppressing HIV-2 infection. The Specific Aims of this proposal are: AIM 1: To determine the clinical, virologic and immunologic outcomes associated with antiretroviral therapy (ART) in a longitudinal prospective HIV-2 infected Senegalese cohort. AIM 2: To assess role of drug resistance in viruses that emerge in HIV-2 infected subjects with virologic failure and to determine if there are qualitative and quantitative differences the drug resistant viruses that emerge between HIV-2 and HIV-1.
描述(由申请人提供):本提案的总体目标是进一步了解强效抗逆转录病毒疗法(ART)对人类免疫缺陷病毒2型(HIV-2)感染的影响。HIV-2的致病性通常低于HIV-1。与HIV-1相比,HIV-2感染的特点是无症状期更长,血浆病毒载量更低,CD 4 + T细胞计数下降较慢,艾滋病死亡率降低,母婴传播率降低,性传播率降低。尽管如此,仍有相当比例的HIV-2感染者最终发展为艾滋病。抗逆转录病毒疗法在资源有限的环境中变得越来越可用。在发现HIV-1和HIV-2的塞内加尔,已经制定了一项国家方案,为那些患有艾滋病、CD 4 + T细胞计数低于200/mm 3或CD 4 + T细胞计数低于350/mm 3并有临床症状的人提供抗逆转录病毒治疗。 然而,ART对HIV-2感染者的结局、免疫应答、病毒载量、动力学和进化、HIV-2耐药性和适应性的影响在很大程度上是未知的。我们来自塞内加尔达喀尔的HIV-2感染受试者的长期纵向队列提供了一个独特的机会来研究ART在抑制HIV-2感染中的作用。该提案的具体目标是:目标1:确定在纵向前瞻性HIV-2感染的塞内加尔队列中与抗逆转录病毒治疗(ART)相关的临床、病毒学和免疫学结局。目标2:评估耐药性在病毒学失败的HIV-2感染受试者中出现的病毒中的作用,并确定HIV-2和HIV-1之间出现的耐药性病毒是否存在定性和定量差异。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Geoffrey Scott Gottlieb其他文献

Infection à VIH-2 au Sénégal: échecs virologiques et résistances aux antirétroviraux (ARV)
塞内加尔 VIH-2 感染:病毒学和抗逆转录病毒 (ARV) 抵抗
  • DOI:
  • 发表时间:
    2019
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Selly Ba;N. Dia;S. E. Hawes;L. Déguénonvo;F. Sall;C. Ndour;Khadim Faye;F. Traoré;Macoumba Touré;M. Sy;Dana Noelle Raugi;N. Kiviat;Robert A. Smith;M. Seydi;P. Sow;Geoffrey Scott Gottlieb
  • 通讯作者:
    Geoffrey Scott Gottlieb

Geoffrey Scott Gottlieb的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Geoffrey Scott Gottlieb', 18)}}的其他基金

Improving Diagnosis, Treatment & Detection of Drug Resistance in HIV-2 Infection
改善诊断、治疗
  • 批准号:
    10189489
  • 财政年份:
    2015
  • 资助金额:
    $ 62.92万
  • 项目类别:
Improving Diagnosis, Treatment & Detection of Drug Resistance in HIV-2 Infection
改善诊断、治疗
  • 批准号:
    10078744
  • 财政年份:
    2015
  • 资助金额:
    $ 62.92万
  • 项目类别:
Improving Diagnosis, Treatment & Detection of Drug Resistance in HIV-2 Infection
改善诊断、治疗
  • 批准号:
    9089930
  • 财政年份:
    2015
  • 资助金额:
    $ 62.92万
  • 项目类别:
Improving Diagnosis, Treatment & Detection of Drug Resistance in HIV-2 Infection
改善诊断、治疗
  • 批准号:
    10398906
  • 财政年份:
    2015
  • 资助金额:
    $ 62.92万
  • 项目类别:
Improving Diagnosis, Treatment & Detection of Drug Resistance in HIV-2 Infection
改善诊断、治疗
  • 批准号:
    9274145
  • 财政年份:
    2015
  • 资助金额:
    $ 62.92万
  • 项目类别:
Improving Diagnosis, Treatment & Detection of Drug Resistance in HIV-2 Infection
改善诊断、治疗
  • 批准号:
    8991978
  • 财政年份:
    2015
  • 资助金额:
    $ 62.92万
  • 项目类别:
Improving Diagnosis, Treatment & Detection of Drug Resistance in HIV-2 Infection
改善诊断、治疗
  • 批准号:
    10652277
  • 财政年份:
    2015
  • 资助金额:
    $ 62.92万
  • 项目类别:
Antiretroviral Therapy for HIV-2 Infection in Senegal
塞内加尔针对 HIV-2 感染的抗逆转录病毒治疗
  • 批准号:
    7836630
  • 财政年份:
    2005
  • 资助金额:
    $ 62.92万
  • 项目类别:
Antiretroviral Therapy for HIV-2 Infection in Senegal
塞内加尔针对 HIV-2 感染的抗逆转录病毒治疗
  • 批准号:
    8469814
  • 财政年份:
    2005
  • 资助金额:
    $ 62.92万
  • 项目类别:
Antiretroviral Therapy for HIV-2 Infection in Senegal
塞内加尔针对 HIV-2 感染的抗逆转录病毒治疗
  • 批准号:
    8660589
  • 财政年份:
    2005
  • 资助金额:
    $ 62.92万
  • 项目类别:

相似海外基金

Unraveling Adverse Effects of Checkpoint Inhibitors Using iPSC-derived Cardiac Organoids
使用 iPSC 衍生的心脏类器官揭示检查点抑制剂的副作用
  • 批准号:
    10591918
  • 财政年份:
    2023
  • 资助金额:
    $ 62.92万
  • 项目类别:
Optimization of mRNA-LNP vaccine for attenuating adverse effects and analysis of mechanism behind adverse effects
mRNA-LNP疫苗减轻不良反应的优化及不良反应机制分析
  • 批准号:
    23K15383
  • 财政年份:
    2023
  • 资助金额:
    $ 62.92万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Elucidation of adverse effects of combined exposure to low-dose chemicals in the living environment on allergic diseases and attempts to reduce allergy
阐明生活环境中低剂量化学品联合暴露对过敏性疾病的不良影响并尝试减少过敏
  • 批准号:
    23H03556
  • 财政年份:
    2023
  • 资助金额:
    $ 62.92万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Green tea-based nano-enhancer as an adjuvant for amplified efficacy and reduced adverse effects in anti-angiogenic drug treatments
基于绿茶的纳米增强剂作为抗血管生成药物治疗中增强疗效并减少不良反应的佐剂
  • 批准号:
    23K17212
  • 财政年份:
    2023
  • 资助金额:
    $ 62.92万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Effects of Tobacco Heating System on the male reproductive function and towards to the reduce of the adverse effects.
烟草加热系统对男性生殖功能的影响以及减少不利影响。
  • 批准号:
    22H03519
  • 财政年份:
    2022
  • 资助金额:
    $ 62.92万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Mitigating the Adverse Effects of Ultrafines in Pressure Filtration of Oil Sands Tailings
减轻油砂尾矿压力过滤中超细粉的不利影响
  • 批准号:
    563657-2021
  • 财政年份:
    2022
  • 资助金额:
    $ 62.92万
  • 项目类别:
    Alliance Grants
1/4-Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
1/4-破译ECT结果和不良反应的机制(DECODE)
  • 批准号:
    10521849
  • 财政年份:
    2022
  • 资助金额:
    $ 62.92万
  • 项目类别:
4/4-Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
4/4-破译ECT结果和不良反应的机制(DECODE)
  • 批准号:
    10671022
  • 财政年份:
    2022
  • 资助金额:
    $ 62.92万
  • 项目类别:
2/4 Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
2/4 ECT 结果和不良反应的破译机制(DECODE)
  • 批准号:
    10670918
  • 财政年份:
    2022
  • 资助金额:
    $ 62.92万
  • 项目类别:
Downsides of downhill: The adverse effects of head vibration associated with downhill mountain biking on visuomotor and cognitive function
速降的缺点:与速降山地自行车相关的头部振动对视觉运动和认知功能的不利影响
  • 批准号:
    2706416
  • 财政年份:
    2022
  • 资助金额:
    $ 62.92万
  • 项目类别:
    Studentship
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了